Larka
banner_2_8_ind.jpg

Home

Since 1993, Larka has been dedicated to Pharma & Biotech technical operations and business strategy consulting.

Founded in 1993 and supported by more than 100 consultants, Larka is delivering renowned, valuable & actionable insight within the pharma & biotech industry - Learn More
 

Our Services

 

BUSINESS INTELLIGENCE

The data you need for decision-making on portfolio strategy, competition, tech & innovation, investment, and geographic expansion.

Learn More ⇀


CONTRACT DEV & MANUFACTURING

Biologics or small molecules, API or finished form, we manage your outsourcing projects from CDMO identification to Tech Transfer.

Learn More ⇀


TECHNICAL OPERATIONS

R&D, manufacturing, quality & CMC, and regulatory consultancy. Small or large molecule, Larka turns your drug substance into a final drug product.

Learn More ⇀


CORPORATE STRATEGY

We assist your business operations in achieving corporate objectives through portfolio strategy, resource allocation, strategic planning and business development.

Learn More ⇀


M&A                             

Sell-side or buy-side, discover how Larka brings value to your M&A transactions.

Learn More ⇀

 
 

Our Clients

Here To Support You.

With more than 20 years of customer experience, we support you with any of your challenges.


PHARMA

Covering Big Pharma to smaller laboratories, we deal with 50+ customers and manage 110+ projects per year. 


BIOTECH

From early to late phase, we  support 30+ Biotechs and manage 60+ projects per year.


CDMOs

Expert in the industry, we assist 40+ CDMOs with their strategic & technical issues - 50+ projects per year.


PRIVATE EQUITY FIRMS

Trusted partner of 10+ PE firms in Europe, we handle 30+ projects per year.

 
 

A Few Examples Of What We've Done


grow_3_mod.jpg

Growth & Value Creation.

Global leader in API manufacturing was facing a steady increase of emerging countries competition. In order to counter this competition and recover an adequate growth, our client needed to identify new growth and value creation leverages.

 
fluids_mod.jpg

Is This Product The One?

Mid-size biotech backed by an investment firm assessed the opportunity to acquire a phase II biotech product. The investment firm required its biotech company to carry-out a due-diligence of this phase 2 biotech product. They requested Larka to handle the due-diligence.

 
 

 
 
We cannot solve our problems with the same thinking we used when we created them.
— Albert Einstein